CO2021017619A2 - Moduladores del receptor alfa relacionado con estrógeno (errα) - Google Patents

Moduladores del receptor alfa relacionado con estrógeno (errα)

Info

Publication number
CO2021017619A2
CO2021017619A2 CONC2021/0017619A CO2021017619A CO2021017619A2 CO 2021017619 A2 CO2021017619 A2 CO 2021017619A2 CO 2021017619 A CO2021017619 A CO 2021017619A CO 2021017619 A2 CO2021017619 A2 CO 2021017619A2
Authority
CO
Colombia
Prior art keywords
errα
modulators
receptor alpha
estrogen
related receptor
Prior art date
Application number
CONC2021/0017619A
Other languages
English (en)
Inventor
Jaap Gerardus Henricus Lemmers
Eugen Deretey
Johannes Petrus Gerardus Klomp
Joseph Maria Gerardus Barbara Cals
Arthur Oubrie
Original Assignee
Lead Pharma Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Pharma Holding Bv filed Critical Lead Pharma Holding Bv
Publication of CO2021017619A2 publication Critical patent/CO2021017619A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se dirige a compuestos de acuerdo con la Fórmula I y sales farmacéuticamente aceptables de los mismos. Los compuestos se pueden usar como moduladores del Receptor Relacionado con Estrógeno alfa (ERRα) y tienen utilidad en el tratamiento de enfermedades o afecciones mediadas por ERRα.
CONC2021/0017619A 2019-07-04 2021-12-21 Moduladores del receptor alfa relacionado con estrógeno (errα) CO2021017619A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19184515 2019-07-04
PCT/EP2020/068574 WO2021001453A1 (en) 2019-07-04 2020-07-01 ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS

Publications (1)

Publication Number Publication Date
CO2021017619A2 true CO2021017619A2 (es) 2022-04-19

Family

ID=67180693

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017619A CO2021017619A2 (es) 2019-07-04 2021-12-21 Moduladores del receptor alfa relacionado con estrógeno (errα)

Country Status (15)

Country Link
US (1) US20220387401A1 (es)
EP (1) EP3994138A1 (es)
JP (1) JP2022538363A (es)
KR (1) KR20220029719A (es)
CN (1) CN114341135A (es)
AR (1) AR119348A1 (es)
AU (1) AU2020298779A1 (es)
BR (1) BR112021026687A2 (es)
CA (1) CA3144891A1 (es)
CO (1) CO2021017619A2 (es)
IL (1) IL289510A (es)
MA (1) MA56444A (es)
MX (1) MX2022000165A (es)
WO (1) WO2021001453A1 (es)
ZA (1) ZA202200591B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4380936A1 (en) * 2021-08-03 2024-06-12 BeiGene, Ltd. Pyrazolopyridinone compounds
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0808445A2 (pt) * 2007-03-07 2014-08-05 Janssen Pharmaceutica Nv TIAZOLIDINADIONAS COMO MODULADORES DE RECEPTOR-a RELACIONADOS COM ESTROGÊNIO
KR20090128454A (ko) * 2007-03-07 2009-12-15 얀센 파마슈티카 엔.브이. 에스트로겐 관련 수용체-알파 조절제로서 치환된 페녹시 아미노티아졸론
CN104119285B (zh) * 2013-04-28 2016-06-29 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用

Also Published As

Publication number Publication date
EP3994138A1 (en) 2022-05-11
CA3144891A1 (en) 2021-01-07
JP2022538363A (ja) 2022-09-01
KR20220029719A (ko) 2022-03-08
US20220387401A1 (en) 2022-12-08
MX2022000165A (es) 2022-05-20
IL289510A (en) 2022-03-01
MA56444A (fr) 2022-05-11
CN114341135A (zh) 2022-04-12
ZA202200591B (en) 2023-07-26
BR112021026687A2 (pt) 2022-03-08
WO2021001453A1 (en) 2021-01-07
AR119348A1 (es) 2021-12-09
AU2020298779A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
CO2021017619A2 (es) Moduladores del receptor alfa relacionado con estrógeno (errα)
CO2022003829A2 (es) Moduladores de receptor alfa relacionado con estrógenos (errα)
CL2017001984A1 (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014)
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CO6501183A2 (es) Piperidinas sustituidas como antagonistas de ccr3
ECSP11011493A (es) 1-(piperidin-4-il)-derivados de pirazol como moduladores de gpr 119
NI201200107A (es) Moduladores alostéricos positivos de receptores m1 de la quinolina amida
PE20181366A1 (es) Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CO2021008998A2 (es) Amidas de pirrolidina iii sustituidas
NI201900075A (es) Compuesto moduladores del receptor de hidrocarburos de arilo (ahr)
UY32858A (es) Derivados de (tio)morfolina como moduladores de sip
PE20171738A1 (es) Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos
CR20160455A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA
DOP2016000311A (es) Nuevos compuestos
CU20140103A7 (es) Compuestos de cromano sustituidos como modulares del receptor sensible al calcio
MA39778A (fr) Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
ECSP20082988A (es) Agonistas de tlr7
BR112018003489A2 (pt) n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
CL2021002946A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CO2022014673A2 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina ii